2017 ELN标准下NPM1/FLT3-ITD基因型对急性髓系白血病预后的影响
该研究基于RATIFY试验的549例FLT3-ITD阳性AML患者,按2017 ELN标准分为4种NPM1/FLT3-ITD基因型,其中318例可完成完整ELN风险分类。
要点
- 2017 ELN定义的NPM1/FLT3-ITD基因型可显著区分AML患者的OS。
- 米哚妥林联合标准化疗在各ELN风险组中均显示一致获益。
- 异基因造血干细胞移植和较低WBC计数也是OS的有利因素。
核心结论
- 按2017 ELN标准划分的NPM1/FLT3-ITD基因型可显著区分FLT3-ITD阳性AML患者的OS。
- 米哚妥林在各ELN风险组中均有一致的生存获益。
研究设计与样本
- 回顾性探索性研究,基于RATIFY随机试验中549例FLT3-ITD阳性AML患者,其中318例可完成完整ELN风险分类。
主要发现
- 1或2个诱导疗程后缓解的显著影响因素为ELN风险组和WBC计数,米哚妥林治疗无影响。
- 多变量Cox模型显示米哚妥林治疗、异基因HCT、ELN预后良好组和较低WBC计数为OS的显著有利因素。
关键数值与推荐
- 4种NPM1/FLT3-ITD基因型基于FLT3-ITD等位基因比值(AR)和NPM1突变状态定义。
- FLT3-ITD高突变/野生型等位基因比值定义为≥0.5。
临床怎么用
- 对FLT3-ITD阳性AML患者应按2017 ELN标准进行NPM1/FLT3-ITD基因型分层以评估预后。
- 米哚妥林联合标准化疗可在各ELN风险组中考虑使用。
局限性
- 本研究为回顾性探索性分析。
- 仅318/549例患者可完成完整ELN风险分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (≥0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 NPM1/FLT3-ITD genotypes differed significantly with regard to clinical and concurrent genetic features. Complete ELN risk categorization could be done in 318 of 549 trial patients with FLT3-ITD AML. Significant factors for response after 1 or 2 induction cycles were ELN risk group and white blood cell (WBC) counts; treatment with midostaurin had no influence. Overall survival (OS) differed significantly among ELN risk groups, with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-, intermediate-, and adverse-risk groups, respectively (P < .001). A multivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in first complete remission as a time-dependent variable revealed treatment with midostaurin, allogeneic HCT, ELN favorable-risk group, and lower WBC counts as significant favorable factors. In this model, there was a consistent beneficial effect of midostaurin across ELN risk groups.
引用
- Döhner K, Thiede C, Jahn N, et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. 2020. PMID: 31826241. doi:10.1182/blood.2019002697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。